In a prospective investigation comparing 68Ga-PSMA PET/CT, NaF-PET/CT, and whole-body MRI in patients with prostate cancer, MRI exhibited the lowest sensitivity (80%) and specificity (83%) among the three methods, making it less advantageous than PET-driven techniques for detecting bone metastases [60]. The gene discussed is FOLH1; the disease is Familial prostate cancer.